Spanish VC Firm Ysios Capital Launches €100 Million InceptionBio Fund to Boost BioTech Startup Creation

A New Dawn for Spanish BioTech

In a significant move for the Spanish biotechnology landscape, Ysios Capital, a venture capital firm renowned for its focus on life sciences, has announced the launch of InceptionBio. This new fund aims to raise €100 million to foster the creation and development of BioTech startups at their earliest stages. With its first closing already secured, the fund is set to become a pivotal player in translating groundbreaking scientific research into impactful medical solutions.

The Strategy Behind InceptionBio

InceptionBio will be helmed by Joan Perelló, Managing Partner at Ysios Capital, alongside partner Arturo Urrios. Their vision is clear: leverage Spain’s world-class scientific research to establish globally impactful BioTech companies. The fund’s strategy centers on technology transfer and early-stage investments, focusing on collaborations with universities, research centers, and scientific entrepreneurs. This approach aims to accelerate the transition of scientific discoveries into viable therapies, enhancing Spain's role in the global BioTech arena.

Strengthening Spain’s BioTech Ecosystem

The involvement of the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte program underscores the strategic importance of this initiative. CDTI-Innvierte’s backing highlights a robust public-private collaboration designed to enhance Spain’s competitiveness in research and development. By fostering innovation-driven companies, InceptionBio is set to significantly boost the nation’s BioTech ecosystem.

Source: Link to original article

Ysios Capital, established in 2008, currently manages over €400 million in assets. Its investment portfolio includes more than 40 BioTech companies, with significant exits through NASDAQ and mergers and acquisitions. Notable transactions include Takeda’s acquisition of Tigenix and Qiagen’s purchase of STAT-Diagnostica, reflecting Ysios Capital’s formidable presence in the sector.

Implications for Startups and Investors

For startups, InceptionBio represents a golden opportunity to access funding and expertise at a critical stage of development. The fund’s focus on early-stage projects means that fledgling companies can benefit from both financial backing and strategic guidance, accelerating their journey from concept to commercialization.

Investors, on the other hand, stand to gain from the fund's targeted approach to identifying high-potential scientific assets. By connecting science, entrepreneurship, and investment, InceptionBio aims to attract top talent and capital, creating a fertile ground for innovation and growth.

A Vision for the Future

Ysios Capital’s strategic initiative with InceptionBio is poised to establish Spain as a leading hub for BioTech innovation. By aligning with both public and private sectors, the fund seeks to create a sustainable ecosystem that nurtures groundbreaking discoveries and translates them into life-saving therapies.

As Arturo Urrios aptly put it, “InceptionBio was created to connect science, entrepreneurship, and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain.” This vision promises not only to enhance Spain’s standing in the global BioTech sector but also to deliver meaningful solutions for patients worldwide.

In conclusion, the launch of InceptionBio marks a significant milestone for Ysios Capital and the broader Spanish BioTech industry. With a strong foundation and strategic vision, the fund is well-positioned to drive innovation and establish Spain as a powerhouse in biotechnology.

Source: Link to original article